Please assess the completion status of the following clinical trial:

Trial Title: The Treatment of Depression With Botulinum Type A Toxin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male/Female between the ages of 18 and 65~2. Major Depression Disorder as defined by DSM IV criteria and diagnosed by a psychiatrist. DSM (Diagnostic and Statistical Manual) IV criteria for depression are: a depressed mood or anhedonia for at least a two week period. This mood must represent a change from the person's normal mood; social, occupational, educational or other important functioning must also be negatively impaired by the change in mood. Major depressive disorder cannot be diagnosed if a person has a history of bipolar disorder or if the depressed mood is better accounted for by substance abuse or a psychotic disorder. In addition, the patient must have 5 of the following symptoms:~   * Significant weight loss or weight gain.~  * Insomnia or hypersomnia~  * Psychomotor agitation or retardation~  * Feelings of worthlessness or excessive guilt~  * Poor Concentration~  * Fatigue or loss of energy~  * Suicidal thoughts~3. History of depression for at least 6 months~4. Initial score 14 or higher on initial Hamilton Depression rating scale.~5. Melancholic facial expressions amenable to treatment with Botox. Photos will be taken of potential participants and ranked independently by two investigators, on a scale of 1-10 based on how negative they look, 10 being the highest. Patients with an average score of 6 or above will be included in the study~Exclusion Criteria:~1. Active substance abuse~2. Bipolar Depression~3. Subjects who are pregnant, nursing or trying to become pregnant during study participation~4. Subjects who are currently on more than 3 psychiatric medications at the time of enrollment~5. Current medications used to treat depression must be stable for at least 60 days prior to enrollment~6. Previous Botox treatment~7. The Principle Investigator has determined that this study is not in the best interest of the subject and therefore the subject will not be enrolled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Botox, Then Placebo (Type: EXPERIMENTAL): At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
- Placebo, Then Botox (Type: EXPERIMENTAL): At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete